Group 1: Company Development Strategy - The company has restructured its development plan since 2014, investing in Xinhuakun Biotechnology to develop recombinant human freeze-dried keratinocyte growth factor (KGF-2), currently in Phase III clinical trials [4] - Health products utilizing biological growth factor technology, such as masks and serums, have been launched and are selling well [4] - The company has successfully acquired Shanghai Suhao Yiming Pharmaceutical Co., Ltd. and is focusing on precision medicine technologies like gene testing and cell therapy [4][6] Group 2: Financial Performance - The company has maintained stable and healthy growth, exceeding the planned profit growth rate of 20% [5] - Historical data shows that growth hormone sales have increased by over 30% annually, while interferon sales have grown by approximately 15% [5] Group 3: Product Development - Xinhuakun has developed pharmaceutical cosmetics, including masks and serums, which were initially sold internally and are now expanding to external sales due to positive feedback [5] - The company plans to introduce more series of products in the future [5] Group 4: Collaboration and Market Expansion - Zhongde Meilian, founded by returnees from the U.S., focuses on forensic diagnostics and is expanding into the gene testing field [6] - The company has established partnerships with public security agencies to provide technical services and is expanding its regional collaborations [6] Group 5: Future Development Strategy - The company aims to position itself in the biopharmaceutical sector, continuing to invest in competitive products and companies [6] - Future collaborations with scientists from Boshengji and Zhongde Meilian will enhance the company's market competitiveness and influence [6]

证券代码：300009 证券简称：安科生物 1 / 6 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2015-004 | --- | --- | --- | |-----------------------|-------------------------------|----------------------------------------------------------------| | | | | | 投资者关系活 | 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 汇添富基金 刘*；中银国际 王*；齐鲁证券资管 张**；中航证 | | 及人员姓名 | 券 沈 ** | ；合心资本 鲁**；广发资管 王*、饶*；西部利得基金 | | | 张* | | | 时间 | 2015 年 06 月 09 日 | | | 地点 | 公司 A 座 901 会议室 | | | | | | ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2016-001 | --- | --- | --- | |--------------|-----------------------------------|--------------------------------------------------| | | | | | 投资者关系活 | 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 国元证券 金*、丁**、朱**；浙商证券 樊**、戴*；鲁 | | 及人员姓名 | 商集团 张 * | ；上海汇利资产 叶*；长盛基金 金*；浦 | | | | 银安盛基金 刘**；景泰利丰 马*；嘉和投资 袁*、龚 | | | * ；双乔资产 谢 | **、卞** ；华宝信托 李*；浙江美浓投 | | | 资 傅**；丰大资管 张 | ** | | 时间 | ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2016-002 | --- | --- | --- | |-----------------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活 | 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | 中泰证券 | 谢**、赵*；富邦证券 王**；保德信投信 陈 | | 及人员姓名 | ** ；复华投资 徐 | **、沈** ；台新投信 叶 ** | | 时间 | 2016 年 9 月 22 日 | 16:00 | | 地点 | 公司 A 座 902 会议室 | | | | | | | 上市公司接待 人员姓名 | 姚建平、李坤、刘文惠 ...

Group 1: Precision Medicine Strategy - The company has expanded from gene engineering pharmaceuticals to precision medicine since 2014, focusing on precision diagnostics and treatments [4] - Precision diagnostics include gene sequencing and testing, with the establishment of a third-party testing platform and the acquisition of a company specializing in gene testing [4] - The establishment of Anke Clover Company focuses on tumor CT-RNA testing, enhancing the company's precision medicine portfolio [4] Group 2: Precision Treatment Developments - The company is actively developing targeted therapies for tumors, including small molecule and large molecule antibody drugs, with the Her-2 monoclonal antibody nearing completion of Phase I clinical trials [4][5] - A contract was signed to acquire PD-1 humanized antibody technology, which is expected to expedite clinical trials significantly [5] - The company has entered the cell therapy field through a 20% stake in a partner company, with ongoing clinical trials in Anhui [5] Group 3: Resource Integration and Subsidiary Management - The company is strategically investing in subsidiaries like Anke Clover and Boshengji to enhance its precision medicine layout, focusing on complementary strengths [5][6] - The full subsidiary, Zhongde Meilian, has performed well this year, with plans to integrate international resources for further development in prenatal screening and second-generation sequencing [6] Group 4: Product Development and Market Strategy - The company is working on long-acting products, with clinical trials for long-acting growth hormone expected to complete by the end of next year [6] - The growth hormone market is anticipated to expand due to increasing patient populations and reasonable pricing for growth hormone powder injections [7] - The company is also focusing on the development of small molecule drugs for cancer and viral infections, alongside modernizing traditional Chinese medicine [7]

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2016-004 | --- | --- | --- | |-----------------|------------------------------|----------------------------------------------------| | | | | | 投资者关系活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | √ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | 证券时报记者程鹏、童璐 | | | 及人员姓名 | | | | 时间 | 2016 年 12 月 19 | 日 15:00 | | 地点 | 公司 A 座 902 | 会议室 | | 上市公司接待 | 王兴兵、杨林、宋社吾、姚建平 | | | 人员姓名 | | | | 投资者关系活 | 2016 年 12 月 | 19 日下午，省立医院王主任、公司高管做 | ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2017-004 | --- | --- | --- | |--------------|---------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | □ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | √ 其他 | （现场交流与网络直播） | | 参与单位名称 ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2017-003 | --- | --- | --- | |-----------------------|------------------------------------------|-------------------------------------------------------------| | | | | | 投资者关系活 动类别 | √ 特定对象调研 □ 媒体采访 | □ 分析师会议 □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称 | 浙商证券 蒋*、蒋**；证券时报 | 童*；浙商资管 戴*；长城财 | | 及人员姓名 | 富资管 胡**；中国健康产业基金 | 应 ** ；财通证券资管 朱 * | | 时间 | 2017 年 8 月 24 日 14:30 | | | 地点 | 公司 A 座 902 会议室 | | | 上市公司接待 人员姓名 | 董事会 ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |-------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------------------| | | | | | 投资者关系活 | √ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ 其他 | （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 浙商证券 蒋 * 、戴 * 樊 ** ；财通证券 沈 * | ；中国平安 梁 * ；景熙资产 张 * ；国联证券 ；万家基金 王 ** ；颐和资产 刘 ** 、叶 * ； | | | 民生证券 ...

Group 1: Company Performance - The company achieved stable growth in the first half of 2017, with a focus on its established business plan [2] - The biological products, particularly recombinant growth hormone, continued to grow rapidly due to high quality and effectiveness in treating children's growth issues [2] - Increased awareness and economic capability among residents contributed to the rising demand for growth hormone treatments [2] Group 2: Product Development and Marketing Strategies - The company is adapting its marketing strategies to promote interferon in various antiviral applications, leading to significant growth in external applications [3] - The revenue share from external interferon products has increased, contributing to a slight overall growth in interferon sales in the first half of the year [3] - The company is advancing the research and development of peptide formulations to enhance sales performance [3] Group 3: Research and Clinical Trials - The company is conducting clinical trials for monoclonal antibody drugs targeting Her-2 and PD-1, with promising prospects for broad anti-tumor efficacy [3] - The company is actively preparing for clinical submissions related to CAR-T technology, focusing on blood cancers and solid tumors [3]